CANCER IMMUNOLOGY IMMUNOTHERAPY

投稿咨询

官方网站：http://www.springer.com/medicine/internal/journal/262

投稿网址：https://www.editorialmanager.com/ciim/default.aspx

PMC链接：http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0340-7004%5BISSN%5D

自1976年成立以来，肿瘤免疫学、免疫治疗(CII)在肿瘤免疫学领域取得了重大进展。该杂志是一个论坛的新概念和进展的基础，翻译，临床癌症免疫学和免疫治疗。CII热衷于发表广泛的观点和评论，扩展或挑战现有范式的结果，以及未能复制支持当前范式的实验的负面研究，以及在不同环境中成功复制他人结果的论文。除了发表原创研究论文和评论，CII还提供以下独特的出版格式:·“聚焦研究综述”，与会议报告一起发表，为每位演讲者提供了机会来扩展他们在会议上提出的想法和概念。·“书面研讨会”，是一系列围绕某一特定问题并针对该领域有争议但具有战略意义的主题的补充论文组成的虚拟研讨会，通常由4-8篇论文和召集人的附带评论组成。CII隶属于癌症免疫治疗协会(CIMT)、加拿大癌症免疫治疗协会(CCIC)、日本癌症免疫协会(JACI)、意大利生物肿瘤免疫治疗网络(NIBIT)、免疫肿瘤免疫治疗和免疫监测协会(CITIM)。

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:·“Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.·“Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Espa?ola de Immunologia-Grupo Espa?ol de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM).